Sanofi has made two key M&A deals in quick succession in order to bolster its pipeline. The company entered into merger agreement with Kadmon Holdings, worth up to US$1.9 B to grow its general medicines core assets with the addition of Rezurock (belumosudil) and just one month prior it acquired Translate Bio, a manufacturer of mRNA Therapeutics that encodes functional protein in a deal which is potentially worth up to US$3.2 B.